All In Biotech

Drug Trial Radar · NCT04994106

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

Jul 27, 2021

Primary completion

Sep 20, 2022

Study completion Sep 20, 2022

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability, and pharmacokinetic (PK) of AZD5462 following single ascending dose (SAD) and multiple ascending dose (MAD) administration in healthy male and female participants and healthy participants of Japanese descent.

Conditions

  • Healthy Participants

Interventions

  • AZD5462Drug

    Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.

  • PlaceboDrug

    Participants will receive Placebo matched to AZD5462.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: Upto Follow-up (Part A: Day 10 ± 3; Part B: Day 19 ± 3)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.